• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Zimmer Biomet touts 7-year results in Mobi-C cervical disc trial

Zimmer Biomet touts 7-year results in Mobi-C cervical disc trial

March 29, 2018 By Fink Densford

Zimmer Biomet

Zimmer Biomet (NYSE:ZBH) yesterday released seven-year follow-up results from a study of its Mobi-C cervical disc device designed for total disc replacement procedures, touting lower pain, maintained motion range and other benefits.

Results from the study were published in the International Journal of Spine Surgery, the Warsaw, Ind.-based company said.

In the study, researchers compared the use of the the Mobi-C cervical total disc replacement system against the previous standard of care, anterior cervical discectomy and fusion, in nearly 600 patients over seven years.

Results indicated that use of the Mobi-C during cTDR procedures was associated with lower pain scores, a maintained range of motion, less adjacent level degeneration and subsequent adjacent level surgeries and a lower rate of secondary surgery when compared to ACDF.

Follow-up rates in the trial ranged from 73.5% to 84.4%, with overall success rates for patients undergoing two-level cTDR of 60.8% versus 34.6% for ACDF. Success rates were more similar between one-level patients, with 55.2% for cTDR patients and 50% for ACDF.

Researchers indicated that the composite success analysis showed the two-level cTDR was superior over ACDF, and that one-level cTDR was non-inferior versus ACDF.

Results also indicated a higher Neck Disability Index success rate in two-level cTDR over ACDF at 79% versus 58%, respectively. More than 86% of patients who received two-level cTDR and 73.9% of patients who underwent ACDF were “very satisfied” with the outcomes at seven years.

“This study further validates the strengths of Mobi-C as a solution for cervical total disc replacement. The positive clinical outcomes remain consistent with previous findings, mainly that Mobi-C continues to deliver positive patient outcomes including efficacy, safety, patient satisfaction and fewer follow-up surgeries. It is particularly important that the clinical effectiveness of cTDR versus ACDF becomes more apparent when treatment increases from one to two levels, indicating a significant benefit for Mobi-C in two-level procedures, which affects an estimated one in three cervical disc patients,” Zimmer Biomet spine division GM Joe Ross said in a press release.

Earlier this week, Zimmer Biomet said it will participate in the US Dept. of Energy’s Better Buildings, Better Plants energy reduction programs as it looks to reduce its carbon footprint in the US and Puerto Rico.

Filed Under: Clinical Trials, Spine Tagged With: Zimmer Biomet

More recent news

  • Carlsmed names chief product and AI officer as it claims CMS reimbursements
  • Integra LifeSciences says Cincinnati plant flooding will cost millions
  • Mendaera rolls out handheld needle robot paired with Butterfly ultrasound probe
  • Edwards earns FDA approval for first-of-its-kind size-adjustable pediatric heart valve
  • Leading medical device experts and MDO launch Medtech Innovation Board

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy